Study researchers aimed to examine associations between financial hardship and self-reported pain among cancer patients initiating systemic treatment between April 2020 and August 2023.

Phase 3 trial data show datopotamab deruxtecan reduces the risk of disease progression or death in patients with metastatic TNBC.

Conferences can be an excellent way to connect with fellow oncologists and stay informed on the latest research. These events are key to providing ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

Investigators sought to train and validate a machine learning model to distinguish paper mill publications from genuine articles and assess the prevalence of paper mill publications.

Investigators assessed the relationship between risk for death and the consumption of ultra-processed foods after a cancer diagnosis, as well as whether chronic disease biomarkers are responsible.

About half of patients with esophageal cancer presented with stage IV disease; 70.5 percent did not undergo surgical resection ...

Investigators conducted this phase III trial to determine whether immunotherapy was more effective when administered early in the day.

Investigators analyzed economic evaluations of adjuvant immunotherapy to assess cost-effectiveness outcomes, quality-adjusted life-year (QALY)/life-year (LY) gains, and methodologic approaches.

In this phase 2a study, researchers aimed to determine whether donor fecal microbiota transplantation improved survival in mRCC patients receiving immunotherapy.

Investigators compared the interval cancer rate in AI-supported mammography screening versus standard double reading without AI.

Although hospital-owned plans are only a sliver of the Medicare Advantage market, their enrollment continues to grow.